← back to search

Richard P. Junghans

Tufts Medical Center · US
Area of research
Immunology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, and Immune Cell Function and Interaction.
h-index
46
citations
7,297
works
181
NIH funding
primary concept
email

Recent publications

HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
Journal for ImmunoTherapy of Cancer 2020cited by 76position: lastdoi
Antigen Specificity Enhances Disease Control by Tregs in Vitiligo
Frontiers in Immunology 2020cited by 75position: middledoi
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
Cancer Gene Therapy 2019cited by 97position: lastdoi
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells
Oncogene 2018cited by 125position: middledoi
Engineering Axl specific CAR and SynNotch receptor for cancer therapy
Scientific Reports 2018cited by 60position: middledoi
Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression
Journal of Leukocyte Biology 2017cited by 48position: middledoi
Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response
The Prostate 2016cited by 264position: firstdoi
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
Cancer Gene Therapy 2016cited by 170position: lastdoi
Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases
Cancer Gene Therapy 2016cited by 113position: middledoi
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Cancer Immunology Immunotherapy 2015cited by 222position: middledoi
T cell exhaustion and Interleukin 2 downregulation
Cytokine 2014cited by 66position: lastdoi
T-Cell Immunotherapy: Looking Forward
Molecular Therapy 2014cited by 65position: middledoi
Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases
Cancer Gene Therapy 2014cited by 41position: middledoi
Biliary obstruction results in PD-1-dependent liver T cell dysfunction and acute inflammation mediated by Th17 cells and neutrophils
Journal of Leukocyte Biology 2013cited by 61position: middledoi
Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
Clinical Cancer Research 2012cited by 138position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Steven C. Katz · Brown University9 papers (2013–2020)N. Joseph Espat · Boston University8 papers (2013–2019)Prajna Guha · University of Westminster7 papers (2015–2020)Marissa Cunetta · Boston University5 papers (2016–2019)Mitchell Thorn · Pfizer (United States)5 papers (2013–2016)Rachel A. Burga · Rodin Therapeutics (United States)3 papers (2013–2015)Lauren A. Licata · Boston University3 papers (2013–2015)Qiangzhong Ma · Beth Israel Deaconess Medical Center3 papers (2012–2016)Alfred Ayala · Brown University2 papers (2013–2015)Ethan Prince · Brown University2 papers (2019–2020)Anthony J. Bais · Providence College2 papers (2012–2016)Cang T. Nguyen · Agricultural Genetics Institute2 papers (2013–2015)George Miller · Holy Name Medical Center2 papers (2016–2018)Gary R. Point · Pfizer (United States)2 papers (2015–2016)Ashley Moody · HCA Healthcare2 papers (2019–2020)John C. Hardaway · Boston University2 papers (2019–2020)Vincent Armenio · Roger Williams Medical Center2 papers (2019–2020)Abdul Saied · Harvard University2 papers (2014–2020) · 2 papers (2014–2016)Ponnandai Somasundar · Boston University1 papers (2017–2017)